help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lai, R.
Right arrow Articles by Gilles, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lai, R.
Right arrow Articles by Gilles, F.
(American Journal of Pathology. 2004;164:2251-2258.)
© 2004 American Society for Investigative Pathology

Signal Transducer and Activator of Transcription-3 Activation Contributes to High Tissue Inhibitor of Metalloproteinase-1 Expression in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma

Raymond Lai*, George Z. Rassidakis*, L. Jeffrey Medeiros*, Latha Ramdas{dagger}, Andre H. Goy{ddagger}, Cathy Cutler*, Yasushi Fujio§, Keita Kunisada§, Hesham M. Amin* and Frederic Gilles

From the Departments of Hematopathology,*Pathology,{dagger}Lymphoma and Myeloma,{ddagger}and Molecular Pathology,The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and the Department of Molecular Medicine,§Graduate School of Medicine, Osaka, Japan

The tissue inhibitor of metalloproteinase-1 (TIMP1) is expressed in a subset of malignant lymphomas and can inhibit tumor spread and promote cell survival. Recent data suggest that TIMP1 expression may be regulated by signal transducer and activator of transcription (STAT)-3. Thus, we tested the hypothesis that TIMP1 expression is related to STAT3 activation in lymphomas, with a focus on anaplastic large cell lymphomas (ALCLs), which are known to express high levels of phosphorylated/active STAT3 (pSTAT3). Specific inhibition of STAT3 with a dominant-negative construct led to concentration-dependent down-regulation of TIMP1 expression in two anaplastic lymphoma kinase (ALK)+ ALCL cell lines, Karpas 299 and SU-DHL-1. Using cDNA microarrays, ALK+ ALCL cell lines consistently expressed the highest TIMP1 level among 29 lymphoma cell lines of various subtypes. The association between TIMP1 expression and high level of STAT3 activation was validated by Western blots and immunostaining using antibodies specific for pSTAT3 and TIMP1. We further evaluated the relationship between TIMP1 expression and STAT3 activation in 43 ALCL tumors (19 ALK+ and 24 ALK) using immunohistochemistry and a tissue microarray. The TIMP1+ group had a mean of 64% pSTAT3+ cells as compared to 23% pSTAT3+ cells in the TIMP1 group (P = 0.002). As expected, TIMP1 positivity was higher in the ALK+ group (15 of 19, 79%) compared with the ALK group (5 of 24, 21%; P = 0.0002) because NPM-ALK restricted to ALK+ tumors was previously shown to activate STAT3. In conclusion, STAT3 directly contributes to the high level of TIMP1 expression in ALK+ ALCL, and TIMP1 expression correlates with high level of STAT3 activation in ALCL. TIMP1, as a downstream target of STAT3, may mediate the anti-apoptotic effects of STAT3.





This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. J. Tartari, R. H. Gunby, A. M. L. Coluccia, R. Sottocornola, B. Cimbro, L. Scapozza, A. Donella-Deana, L. A. Pinna, and C. Gambacorti-Passerini
Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase
J. Biol. Chem., February 15, 2008; 283(7): 3743 - 3750.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. Dien, H. M. Amin, N. Chiu, W. Wong, C. Frantz, B. Chiu, J. R. Mackey, and R. Lai
Signal Transducers and Activators of Transcription-3 Up-Regulates Tissue Inhibitor of Metalloproteinase-1 Expression and Decreases Invasiveness of Breast Cancer
Am. J. Pathol., August 1, 2006; 169(2): 633 - 642.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
E. Jacobsen
Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type
Oncologist, July 1, 2006; 11(7): 831 - 840.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. D. Alexander
Role for {alpha}-DGK in ALK+ ALCL
Blood, September 15, 2005; 106(6): 1894 - 1895.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Moog-Lutz, J. Degoutin, J. Y. Gouzi, Y. Frobert, N. B.-d. Carvalho, J. Bureau, C. Creminon, and M. Vigny
Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin
J. Biol. Chem., July 15, 2005; 280(28): 26039 - 26048.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society for Investigative Pathology.